In contrast to preclinical [28] and clinical studies [32] examining MAb mediated inhibition of IL-2Rα in non-lymphopenic individuals, our cumulative data suggests that in TMZ treated patients with GBM, a single infusion of daclizumab effectively depletes TRegs without notably impacting the CD4+ or CD8+ effector T-cell compartments. This evidence concerns the gene CD8A and glioblastoma.